| CEO Name | Belen Garijo |
| Nationality | Spain |
| Net Worth Estimation | $50 million |
Belen Garijo's estimated net worth of around $50 million derives from her high executive compensation, stock awards, and long-standing leadership roles at Merck KGaA and previous pharmaceutical companies. Her financial profile reflects accumulated earnings, bonuses, and vested shares as the current CEO and as a former COO of Merck Healthcare.
Belen Garijo's estimated net worth of $50 million places her in the upper 8.2% of CEO net worths within the pharmaceutical industry range of $10 million to $500 million. Her wealth is significantly above the minimum but far below the industry's maximum CEO net worth.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Belen Garijo Performance in Merck KGaA
Belen Garijo, CEO of Merck KGaA, demonstrates strategic leadership focused on innovation and digital transformation, enhancing the company's global healthcare and life science sectors. Her decisive actions in expanding R&D investments and driving sustainability initiatives have significantly improved Merck's competitive position and financial performance. Under her leadership, Merck has achieved robust growth, strengthened its scientific portfolio, and enhanced shareholder value.
Latest News
Merck KGaA appoints Kai Beckmann as new CEO succeeding Belen Garijo in May 2026. Beckmann, currently leading the Electronics division, will take over after Garijo's 15-year tenure, marking a leadership transition amid geopolitical challenges and continued growth in healthcare and semiconductor sectors[12].
The company continues organic growth with strong sales in Life Science and Healthcare, including blockbusters Mavenclad and Erbitux, alongside strategic divestments and acquisitions such as SpringWorks.
Source: http://www.merckgroup.com/en/news/q2-2025-07-08-2025.html